SPI Inks Exclusive Distributorship Agreement with Biotech Firm EVERZOM By CIOTechOutlook Team

SPI Inks Exclusive Distributorship Agreement with Biotech Firm EVERZOM

CIOTechOutlook Team | Saturday, 03 June 2023, 02:28 IST

Summit Pharmaceuticals International and EVERZOM, SAS*, a firm based in France that offers exosome manufacturing services, have inked an exclusive distributorship agreement for Japan.

Exosomes are vesicles that range in size from thirty to hundreds of nanometers that are released by cells. They are enclosed in a lipid bilayer membrane and contain proteins, microRNAs, and other materials. Exosomes have been discovered to have specific impacts on the human body, represented by things like tissue repair. They are recognised to play a crucial role as a communication mediator between cells.

Focusing on this function, exosomes are starting to be researched/used by numerous universities, biotech, and pharmaceuticals for a variety of purposes, such as for the prevention of skin sagging, as well as for the treatment of joint injury. The aim is to establish exosomes as one of the primary therapeutic modalities for the next generation of breakthrough biotherapeutics.

From the beginning, SPI concentrated on the commercial potential of exosomes and offered a range of services based on terms like "cells for exosome production" and "analysis and exploration of molecules encapsulated in exosomes," etc. With the inclusion of the exosome production service from EVERZOM, SPI is now able to help exosome research and development from a variety of angles, particularly with regard to exosome manufacture, engineering, quality control, and regulatory advise.

A Contract Development and Manufacturing Organisation (CDMO) focused on exosomes, EVERZOM was established in 2019 and separated from the CNRS Laboratory at the University of Paris Cité. Only a few CDMOS in the world have the ability to produce exosomes, and one of them is EVERZOM. The company's strength is its patented technology, which enables it to produce large numbers of exosomes in a short amount of time by stimulating cells with turbulence. The company is already collaborating on joint development with several European companies with an eye towards potential use in pharmaceutical applications.